NASDAQ: ACRV
Acrivon Therapeutics Inc Stock Ownership - Who owns Acrivon Therapeutics?

Insider buying vs selling

Have Acrivon Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Peter BlumejensenCEO;Pres2026-08-2514,036$2.21
$30.96kSell
Peter BlumejensenCEO;Pres2026-08-18484$2.01
$972.84Sell
Mary MillerCLO2026-08-18185$2.01
$371.85Sell
Eric DevroeCOO2026-08-18604$2.01
$1.21kSell
Katharine PetersonCAO2026-08-18101$2.01
$203.01Sell
Peter BlumejensenCEO;Pres2026-08-181,229$2.01
$2.47kSell
Erick GamelinCXO2026-08-18400$2.01
$804.00Sell
Adam D. LevyCFO2026-08-041,142$1.57
$1.79kSell
Mary MillerCLO2026-07-21573$1.76
$1.01kSell
Peter BlumejensenPresident and CEO2026-05-2113,729$1.79
$24.57kSell

1 of 4

ACRV insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ACRV insiders and whales buy or sell their stock.

ACRV Shareholders

What type of owners hold Acrivon Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Chione Ltd8.98%3,848,632$7.93MInsider
Kristina Masson8.61%3,691,232$7.60MInsider
Peter Blumejensen7.69%3,296,252$6.79MInsider
Perceptive Advisors LLC7.24%3,104,139$6.39MInsider
Wellington Biomedical Innovation Master Investors Cayman I LP2.07%888,130$1.83MInsider
Ra Capital Management LP0.99%426,302$878.18kInsider
Eric Devroe0.34%146,349$301.48kInsider
Mary Miller0.19%82,009$168.94kInsider
Adam D. Levy0.15%66,008$135.98kInsider
Erick Gamelin0.12%52,592$108.34kInsider

1 of 3

ACRV vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ACRV0.05%36.80%Net BuyingNet Selling
VRCA0.02%99.98%Net BuyingNet Buying
FBIO0.02%49.61%Net Buying
ICCC0.01%21.31%Net BuyingNet Buying
RLYB0.01%99.99%Net BuyingNet Buying

Acrivon Therapeutics Stock Ownership FAQ

Who owns Acrivon Therapeutics?

Acrivon Therapeutics (NASDAQ: ACRV) is owned by 0.05% institutional shareholders, 36.80% Acrivon Therapeutics insiders, and 63.15% retail investors. Chione Ltd is the largest individual Acrivon Therapeutics shareholder, owning 3.85M shares representing 8.98% of the company. Chione Ltd's Acrivon Therapeutics shares are currently valued at $8.20M.

If you're new to stock investing, here's how to buy Acrivon Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.